Ireland-based drug developer Elan has spun out its research and development unit but will retain a 14% to 18% stake.

Elan will fund the drug discovery unit, Neotope Biosciences, and will provide $130m, which is about two years’ worth of funding for its research, according to news provider Fierce Biotech.

Dale Schenk is chief executive of Neotope.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?